StreetAlpha.app
Home › Stocks › NAGE

Niagen Bioscience, Inc. (NAGE)

Healthcare
$1.84
▼ −1.60%
LAST CLOSE · NOV 20

Niagen Bioscience makes Tru Niagen dietary supplements and supplies the Niagen ingredient to food makers and pharmaceutical facilities. It last closed at $1.84 on Nov 20, down 1.60% on the day. The next earnings report for NAGE is expected around Wed, Mar 3, 2027, after the close. For the quarter ended Sep 2026, NAGE reported EPS of -$0.01 on revenue of $27.2M, with revenue down 20.0% from a year ago. Over its last 8 reports the stock moved an average of 14.4% the session after earnings.

AI Auto Pilots
Is NAGE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NAGE.

Key Stats

Last 12 months
Results
Revenue
$122.3M
−1.9% vs a year ago
Net income
$10.2M
−49.9% vs a year ago
EPS (diluted)
$0.12
−50.0% vs a year ago
Gross margin
63.9%
$78.1M gross profit
Valuation
Market cap
$145.7M
79.2M shares
P/E
15.3
Price over 12 month EPS
Price to sales
1.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$69.5M
At Sep 30
Shareholder equity
$83.1M
Buybacks
$5.4M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $67.4M$67.4MFY2021FY2022: $72.0M$72.0MFY2022FY2023: $83.6M$83.6MFY2023FY2024: $99.6M$99.6MFY2024FY2025: $129.4M$129.4MFY2025

From NAGE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Mar 3
Estimated date · After the close
Reported EPS
-$0.01
Quarter ended Sep 2026
Year ago EPS
$0.05
−120.0% on a GAAP basis
Revenue
$27.2M
−20.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.09Dec '24Mar 2025: $0.06Mar '25Jun 2025: $0.04Jun '25Sep 2025: $0.05Sep '25Dec 2025: $0.05Dec '25Mar 2026: $0.07Mar '26Jun 2026: $0.01Jun '26Sep 2026: -$0.01Sep '26Latest -$0.01
Revenue by quarter
Dec 2024: $29.1MDec '24Mar 2025: $30.5MMar '25Jun 2025: $31.1MJun '25Sep 2025: $34.0MSep '25Dec 2025: $33.8MDec '25Mar 2026: $31.5MMar '26Jun 2026: $29.8MJun '26Sep 2026: $27.2MSep '26Latest $27.2M
How NAGE moved after its last 8 reports
Average move the session after a report ±14.4%
Nov 4, 2026After the close−16.5%
Aug 4, 2026After the close−14.7%
May 6, 2026After the close−15.7%
Mar 4, 2026After the close+3.2%
Nov 4, 2025After the close−1.0%
Aug 6, 2025After the close+2.2%
May 7, 2025After the close+9.3%
Mar 4, 2025After the close+52.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on NAGEStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on NAGE
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on NAGE

Technical Analysis

NAGE · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 20% below its 20 day and 38% below its 50 day average. It is 97% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), oversold. The nearest support is the Pivot at $1.83, and the nearest resistance the Pivot R1 at $1.87.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 6.6%/day
Key levels
$7.1252 week high+287.0%
$3.63200 day average+97.3%
$2.89100 day average+57.1%
$2.58Swing high (Oct 29)+40.2%
$2.5550 day average+38.6%
$2.2120 day average+20.1%
$1.87Pivot R1+1.6%
$1.84Last close
$1.83Pivot−0.5%
$1.80Pivot S1−2.2%
$1.7952 week low−2.7%
Indicators
RSI (14)29.74Oversold below 30Oversold
MACD-0.19Below its signal lineBearish
Stochastic6.0Near the bottom of its rangeOversold
ADX (14)37.5Trending down
Williams %R-93.8Oversold below −80, overbought above −20Oversold
CCI (20)-134.8Oversold below −100, overbought above 100Oversold
Rate of change−11.1%Change over 10 sessionsBearish
ATR (14)$0.12Typical daily range, 6.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NAGE

What happened before

See how NAGE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow NAGE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How NAGE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for NAGEHow many large options trades hit NAGE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

NAGE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●64 buying vs 70 selling
  • ▼Held by funds -2.2 pts
  • ▼Funds holding -16
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding124140−11.4%
In funds' top 1000–
Held by funds38.1%40.4%−2.2 pts
New / increased15 / 4924 / 38+3.2%
Reduced / sold out39 / 3160 / 26−18.6%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NAGE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

NAGE Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 14, 2025Ozan PamirCFOBuy6,685$6.82$46K
Mar 7, 2025Carlos Luis LopezSVP, General CounselBuy273$7.86$2K
Dec 13, 2024Frank L Jaksch JrDirectorSale37,161$6.19$230K
Nov 22, 2024Ozan PamirCFOBuy2,907$7.36$21K
Every insider buy and sale for NAGE over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See NAGE insider trades →

From SEC Form 4 filings by NAGE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NAGE is in one of them and how their past NAGE trades turned out.

NAGE in the AI portfolios
Loading…

NAGE News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NAGE in an article yet. Here's the latest on the wider market.

NAGE in the news

About Niagen Bioscience

Niagen Bioscience is a bioscience company based in Los Angeles, California, focused on healthy aging. It sells Tru Niagen dietary supplements to consumers directly and through online marketplaces and distribution partners in many countries. It also supplies its Niagen ingredient, a form of vitamin B3, to food and supplement makers and to outsourcing facilities that prepare injectable products. Its pharmaceutical work on NAD+ precursors is still in research and development and does not yet generate revenue.

Headquarters
Los Angeles, CA